NAUTILUS BIOTECHNOLOGY

Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022

13 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

Nautilus Biotechnology Reports First Quarter 2022 Financial Results

03 May 2022 06:00:00 By Nasdaq GlobeNewswire

Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development

12 Apr 2022 08:00:03 By Nasdaq GlobeNewswire

Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022

07 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Nautilus Biotechnology to Present at EuPA and AACR Meetings

04 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

31 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results

24 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Nautilus to Participate in the 42nd Annual Cowen Health Care Conference

16 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

27 Jan 2022 08:00:00 By Nasdaq GlobeNewswire

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

02 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Nautilus Biotechnology Reports Third Quarter 2021 Financial Results

02 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021

11 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

Nautilus to Participate in the Morgan Stanley Global Healthcare Conference

03 Sep 2021 09:00:00 By Nasdaq GlobeNewswire

Nautilus Biotechnology Reports Second Quarter 2021 Financial Results

10 Aug 2021 06:00:00 By Nasdaq GlobeNewswire